Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Mineralocorticoid receptor antagonist, already registered for the treatment of other diseases.
Main Inclusion Criteria: Adult patients recently discharged from the hospital due to heart failure with an ejection fraction >40%.
Status: In preparation
Start of Patient Enrollment: August 2024